CYTOKINETICS, INCORPORATED Revenue
CYTOKINETICS, INCORPORATED (CYTK) reported Revenue of $28.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $28.62M, a 57.13% decline year-over-year.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $19.36M, a 1125.78% increase year-over-year.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $17.75M, a 4.89% increase year-over-year.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.94M, a 318.14% increase year-over-year.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for fiscal 2025 was $88.04M, a 376.56% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for fiscal 2024 was $18.47M, a 145.34% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for fiscal 2023 was $7.53M, a 92.04% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED revenue from contract with customer, excluding assessed tax for fiscal 2022 was $94.59M, a 34.30% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.62M 10-Q · filed 2026-08-06 | $47.98M 10-Q · filed 2026-08-06 | $65.73M derived: sum of 3 quarters · filed 2026-08-06 | $67.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $19.36M 10-Q · filed 2026-05-05 | $37.11M derived: sum of 2 quarters · filed 2026-05-05 | $39.05M derived: sum of 3 quarters · filed 2026-05-05 | $105.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $17.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.69M derived: sum of 2 quarters · filed 2026-02-26 | $86.46M derived: sum of 3 quarters · filed 2026-08-06 | $88.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.94M 10-Q · filed 2025-11-05 | $68.70M derived: sum of 2 quarters · filed 2026-08-06 | $70.28M 10-Q · filed 2025-11-05 | $87.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $66.77M 10-Q · filed 2026-08-06 | $68.35M 10-Q · filed 2026-08-06 | $85.28M derived: sum of 3 quarters · filed 2026-08-06 | $85.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.58M 10-Q · filed 2026-05-05 | $18.51M derived: sum of 2 quarters · filed 2026-05-05 | $18.97M derived: sum of 3 quarters · filed 2026-05-05 | $19.22M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $16.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.39M derived: sum of 2 quarters · filed 2026-02-26 | $17.64M derived: sum of 3 quarters · filed 2026-02-26 | $18.47M 10-K · filed 2026-02-26 |
| 2024-09-30 | $463.00K 10-Q · filed 2025-11-05 | $712.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.55M 10-Q · filed 2025-11-05 | $3.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $249.00K 10-Q · filed 2025-08-07 | $1.08M 10-Q · filed 2025-08-07 | $2.76M derived: sum of 3 quarters · filed 2026-02-26 | $3.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $835.00K 10-Q · filed 2025-05-06 | $2.51M derived: sum of 2 quarters · filed 2026-02-26 | $2.88M derived: sum of 3 quarters · filed 2026-02-26 | $3.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.05M derived: sum of 2 quarters · filed 2026-02-26 | $2.92M derived: sum of 3 quarters · filed 2026-02-26 | $7.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | $378.00K 10-Q · filed 2024-11-07 | $1.25M derived: sum of 2 quarters · filed 2024-11-07 | $5.86M 10-Q · filed 2024-11-07 | $7.82M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $867.00K 10-Q · filed 2024-08-09 | $5.48M 10-Q · filed 2024-08-09 | $7.44M derived: sum of 3 quarters · filed 2025-02-27 | $9.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.61M 10-Q · filed 2024-05-10 | $6.57M derived: sum of 2 quarters · filed 2025-02-27 | $9.09M derived: sum of 3 quarters · filed 2025-02-27 | $98.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.47M derived: sum of 2 quarters · filed 2025-02-27 | $93.44M derived: sum of 3 quarters · filed 2025-02-27 | $94.59M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.52M 10-Q · filed 2023-11-03 | $91.48M derived: sum of 2 quarters · filed 2023-11-03 | $92.63M 10-Q · filed 2023-11-03 | $148.23M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $88.97M 10-Q · filed 2023-08-03 | $90.12M 10-Q · filed 2023-08-03 | $145.72M derived: sum of 3 quarters · filed 2024-02-28 | $151.15M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.15M 10-Q · filed 2023-05-05 | $56.75M derived: sum of 2 quarters · filed 2024-02-28 | $62.19M derived: sum of 3 quarters · filed 2024-02-28 | $65.03M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $55.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $61.04M derived: sum of 2 quarters · filed 2024-02-28 | $63.88M derived: sum of 3 quarters · filed 2024-02-28 | $70.43M 10-K · filed 2024-02-28 |
| 2021-09-30 | $5.44M 10-Q · filed 2022-11-04 | $8.28M derived: sum of 2 quarters · filed 2022-11-04 | $14.83M 10-Q · filed 2022-11-04 | $21.55M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $2.84M 10-Q · filed 2022-08-05 | $9.39M 10-Q · filed 2022-08-05 | $16.11M derived: sum of 3 quarters · filed 2023-03-01 | $57.80M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $6.55M 10-Q · filed 2022-05-06 | $13.27M derived: sum of 2 quarters · filed 2023-03-01 | $54.96M derived: sum of 3 quarters · filed 2023-03-01 | $58.55M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $48.41M derived: sum of 2 quarters · filed 2023-03-01 | $52.00M derived: sum of 3 quarters · filed 2023-03-01 | $55.83M 10-K · filed 2023-03-01 |
| 2020-09-30 | $41.69M 10-Q · filed 2021-11-05 | $45.28M derived: sum of 2 quarters · filed 2021-11-05 | $49.11M 10-Q · filed 2021-11-05 | $54.32M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $3.59M 10-Q · filed 2021-08-06 | $7.42M 10-Q · filed 2021-08-06 | $12.63M derived: sum of 3 quarters · filed 2022-02-25 | $18.68M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $3.83M 10-Q · filed 2021-05-07 | $9.04M derived: sum of 2 quarters · filed 2022-02-25 | $15.09M derived: sum of 3 quarters · filed 2022-02-25 | $22.23M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.27M derived: sum of 2 quarters · filed 2022-02-25 | $18.40M derived: sum of 3 quarters · filed 2022-02-25 | $26.87M 10-K · filed 2022-02-25 |
| 2019-09-30 | $6.05M 10-Q · filed 2020-11-06 | $13.19M derived: sum of 2 quarters · filed 2020-11-06 | $21.66M 10-Q · filed 2020-11-06 | $31.03M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $7.14M 10-Q · filed 2020-08-07 | $15.60M 10-Q · filed 2020-08-07 | $24.98M derived: sum of 3 quarters · filed 2021-02-26 | $35.62M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $8.46M 10-Q · filed 2020-05-08 | $17.84M derived: sum of 2 quarters · filed 2021-02-26 | $28.48M derived: sum of 3 quarters · filed 2021-02-26 | $34.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $20.02M derived: sum of 2 quarters · filed 2021-02-26 | $26.23M derived: sum of 3 quarters · filed 2021-02-26 | $31.50M 10-K · filed 2021-02-26 |
| 2018-09-30 | $10.64M 10-Q · filed 2019-11-01 | $16.86M derived: sum of 2 quarters · filed 2019-11-01 | $22.12M 10-Q · filed 2019-11-01 | |
| 2018-06-30 | $6.21M 10-Q · filed 2019-08-09 | $11.48M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $5.27M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $13.37M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |